2. UroToday Home
  3. Center Of Excellence
  4. Imaging Center

The Latest Research on Urology Imaging

Conferences

Lantheus to Present Additional Clinical Data from Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024

Reno, Nevada (UroToday.com) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced that Oliver Sartor, MD, Director of Radiopharmaceutical Trials and Professor of Medical Oncology at the Mayo Clinic in Rochester, Minnesota, will deliver an oral presentation, including additional clinical data from PNT2002’s initial December 2023 readout, during the European Society of Medical Oncology (ESMO) Annual Meeting in Barcelona on Sunday, September 15, 2024.

WCET 2024: Robot Radical Prostatectomy: How to Achieve Better Continence Outcomes

(UroToday.com) On Thursday, August 15, 2024, during the WCET 2024, a plenary panel session was dedicated to discussing robotic radical prostatectomy and strategies to achieve better continence outcomes for patients undergoing the procedure. The session, moderated by Dr. Atsushi Takenaka, MD, PhD, opened with an emphasis on the critical importance of continence outcomes and their profound impact on patients' quality of life.

WCET 2024: Xi and SP Nephroureterectomy and Bladder Cuff

(UroToday.com) At the third World Congress of Endourology and Uro-Technology, WCET 2024, a plenary discussion was dedicated to Urothelial Cancer, with a particular emphasis on Cystectomy and Nephroureterectomy. The session featured a panel of three experts, moderated by a leading authority in the field. Among the panelists, Dr. Ravi Munver and Dr. Jeffery Nix were invited to provide a comprehensive comparison of the XI versus SP robotic approaches for managing nephroureterectomy and bladder cuff excision.

WCET 2024: What are the Most Important Outcomes in Stone Disease?

(UroToday.com) The 2024 World Congress of Endourology and Uro-Technology Conference continued its Thursday morning plenary session with a discussion on important stone disease outcomes, moderated by the esteemed Dr. Hassan Razvi. The session brought together key experts in stone disease to explore outcomes including quality of life, cost, stone-free rates, and complications associated with kidney stone treatment.

WCET 2024: Dietary Management in Urolithiasis Patients: Myths & Truths

Dr. Penniston opened the plenary on "Myths and Misconceptions of Diet and Stone Prevention" with an engaging discussion. She deconstructed the turbulence regarding dietary advice for stone prevention, which in part arises from the complexity of the condition, with various stone types posing unique etiologies and risk factors. She proceeded to refute the traditional “one-size-fits-all” approach to dietary advice, as it is dually illogical and culturally insensitive.

WCET 2024: Leave No Stone Unmeasured: A Comparison of Three Methods for Determining Stone Volume

(UroToday.com) On the fourth day of the WCET 2024 Annual Meeting in Seoul, South Korea, the twenty-fifth moderated poster session included the work of Mr. D. Daniel Baldwin of Loma Linda Urology. Here, he presented work regarding a comparison of volumetric stone measurement methods.

WCET 2024: Panel: How to Manage Multiple Small Renal Masses

(UroToday.com) At the annual WCET 2024, a plenary session included a panel on the management of multiple small renal masses (SRMs). This included a presented argument by respective conservative, intermediate, and prompt approaches moderated by Dr. Woong Kyu Han, MD. Honored panelists included Dr. Jason Y. Lee, MD, MHPE, FRCSC, Dr. Orit Raz, MD, and Dr. Jaime Landman, MD.

WCET 2024: What's Next in Urologic Robotics: Future Perspectives

(UroToday.com) The Thursday morning plenary session at the 2024 World Congress of Endourology and Uro-Technology Conference in Seoul was presented by Dr. Jeremy Teoh on the rapidly evolving world of urologic robotics.

WCET 2024: Assessment Of Post-Operative Outcomes Following Robotic assisted Mini- Percutaneous Nephrolithotomy With The Monarch™ Platform, Urology

(UroToday.com) At the WCET 2024 conference, Dr. Margaret Knoedler unveiled promising early results of robotic-assisted mini-percutaneous nephrolithotomy (mini-PCNL) using the MONARCH™ Platform. The MONARCH™ Platform, developed by Johnson & Johnson MedTech, represents a significant advancement in the field, designed to enhance percutaneous access and streamline the treatment of large renal stones. A retrograde ureteroscope is inserted and operated by the surgeon using a handheld controller.

WCET 2024: Prospective Randomized Trial Comparing High Power Ho:YAG and Thulium Fiber Laser for Ret- Retrograde Ureteroscopy: Preliminary Clinical Results, Environmental Noise Analysis, and Surgeon Satisfaction.

(UroToday.com) At the WCET 2024 conference, Dr. Wilson Molina from the University of Kansas Medical Center presented a study comparing the intraoperative and postoperative outcomes of the SOLTIVE Thulium Fiber Laser (TFL) with the high-power Holmium:yttrium-aluminum-garnet (Ho:YAG) laser during flexible ureteroscopy (fURS). This study also assessed physician satisfaction between the two laser systems, focusing on a variety of critical factors, including but not limited to noise and effort to concentrate.

WCET 2024: Extraperitoneal and Transvesical Approaches to SP RALP

(UroToday.com) This was a special plenary held by two esteemed urologists, Dr. Jihad Kaouk and Dr. Ryan Nelson, who gave a talk on extraperitoneal and transvesical approaches to single-port robotic radical prostatectomy.

WCET 2024: Pulp Fiction: Vitamin C Supplementation and Risk of Kidney Stones

(UroToday.com)In the medical management of stones moderated poster session, Dr. Daniel Jhang presented his research on the impact of vitamin C supplementation on urinary parameters that are crucial in the formation of kidney stones. Vitamin C is one of the most commonly taken supplements and recently the incidence of urolithiasis has risen. This study comes in response to growing concerns over the increased incidence and complexity of kidney stones coinciding with higher vitamin C intake during the COVID-19 pandemic. Vitamin C is thought to contribute to stone formation via oxalate which is byproduct of the metabolism of Vitamin C.

WCET 2024: Getting into Focal Therapy: Why Your Robotic Practice Should Include FT

(UroToday.com) At the WCET 2024 conference, a plenary session focused on the importance of Focal Therapy in robotic practice, with Dr. Indy Gill delivering a compelling presentation. He began by emphasizing his key takeaway: clinical practice should be guided by level 1 evidence, with data-driven planning for localized prostate cancer. Dr. Gill cautioned against treating the entire prostate gland, as it often leads to significant morbidities without offering real oncological benefits. He argued that for men with intermediate-risk prostate cancer, whole-gland treatment might do more harm than good, whereas Focal Therapy presents a balanced approach that can preserve function while maintaining good oncologic outcomes.

WCET 2024: Panel: New Approaches for Stone Retrieval

(UroToday.com) On the third day of the annual World Congress of Endourology and Technology 2024, the fourth plenary session entitled “Stone Disease and Treatment” included an expert panel on new approaches for stone retrieval. This session was moderated by Paksi Satyagraha, MD of Saiful Anwar General Hospital, Indonesia, with panelists including: Han Kyu Chae, MD, PhD of Kangdong Sacred Heart Hospital in Seoul, Republic of Korea, Sundaram Palaniappan, MD of Sengkang General Hospital, Singapore, Joseph C. Liao, MD of Stanford Medicine, and Steffi Yuen, MD of New Territories East Cluster Hospitals, Hong Kong.

WCET 2024: Managing Complications During Robotic Surgery

(UroToday.com) The 2024 World Congress of Endourology and Uro-Technology Conference in Seoul, Korea, continued its tradition of delivering cutting-edge educational sessions with Wednesday afternoon’s SURS plenary, which focused on the topic of managing complications during robotic surgery. The session was led by Dr. Rene Sotelo, who emphasized the importance of reviewing surgical complications as a means of continuous improvement and enhancing patient outcomes.

WCET 2024: Retroperitoneal Approach-Xi and SP

(UroToday.com) In his engaging and insightful presentation, Dr. Richard Link, humorously referring to himself as a "reinvented transperitoneal curmudgeon," took the audience on a journey through the evolution of surgical techniques in urology, emphasizing the importance of adaptability and innovation in the field.

WCET 2024: Flexible and Navigable Suction Ureteral Access Sheath Revolutionizes Retrograde Intrarenal Surgery: A Prospective Study by the Global FANS Collaborative Group & EAU Section of Urolithiasis

(UroToday.com) At the WCET 2024 conference, Dr. Steffi Kar Kei Yuen from the SH Ho Urology Centre at The Chinese University of Hong Kong presented significant findings from a multi-center study on the stone-free rate (SFR) and complications following flexible ureteroscopy (F-URS) for renal stones using the flexible and navigable suction ureteral access sheath (FANS). This large-scale study, conducted across 25 centers worldwide, represents one of the most extensive prospective analyses in the field, offering critical insights into the efficacy and safety of suction UAS during flexible ureteroscopy.

WCET 2024: An In Vitro Assessment of the ILY Robotics Assisted Tele-Console System in Ureteroscopy among Medical Students and Surgeons: Does Video-Gaming Experience Influence the Learning Curve?

(UroToday.com) In the Laparoscopic and Robotic New Technology Moderated poster session of the 2024 WCET, Dr. Aideen Madden presented her research on the initial learning curve associated with the Ily robotics system for flexible ureteroscopy. The study aimed to explore whether prior video gaming experience (VGE) influenced the learning curve when using the robotic system.

WCET 2024: Panel: Techniques of Robotic Simple Prostatectomy

(UroToday.com) The fifth plenary session of the World Congress of Endourology and Technology 2024 Annual Meeting featured a panel moderated by Dr. Taek-Sang Kim of Yale Medicine entitled “Techniques of Robotic Simple Prostatectomy”, showcasing three different robotic approaches to simple prostatectomy. Panelists for this session included three expert robotic prostate surgeons: Dr. David I. Lee, MD, FACS of the University of California, Irvine, California, Dr. Benjamin Waldorf, MD of the University of Tennessee College of Medicine, Chattanooga, Tennessee, and Dr. Mutahar Ahmed, MD, FACS of Hackensack Meridian Health, New Jersey, USA.

WCET 2024: Panel: The Forefront of Laser Technology: Optimizing Stone Treatment

(UroToday.com) The 2024 World Congress of Endourology and Uro-Technology Conference in Seoul, Korea, continued its Wednesday afternoon plenary session, with a discussion on optimizing stone treatment. Moderated by Dr. Michelle Jo Semins, the session brought together leading experts to discuss different laser modalities.

Page 1 of 577
Physician-Scientist Review Articles
State of the Evidence Review Articles
Written by Rashid Sayyid, MD MSc, & Zachary Klaassen, MD MSc
October 19, 2022

Although definitive local therapy in the form of radical prostatectomy or radiation therapy with or without ADT offers excellent long-term outcomes for the majority of patients with clinically localized prostate cancer, patients with high-risk disease experience primary treatment failure rates approaching 65%.1 Disease persistence/recurrence in such patients may be restricted to the prostatic fossa, pelvic lymph nodes, non-regional lymph nodes (M1a), bones (M1b), or the viscera (M1c).

Written by Rashid Sayyid, MD MSc, & Zachary Klaassen, MD MSc
October 20, 2022
Conventional imaging using CT and bone scan has limited sensitivity when staging men with high-risk localized prostate cancer. Findings of extraprostatic spread in the form of extraprostatic extension and/or lymph node, visceral, or bone metastasis can influence treatment planning, and thus, potentially, patient outcomes.
Written by Rashid Sayyid, MD MSc, & Zachary Klaassen, MD MSc
October 13, 2022

Imaging plays a significant role in the diagnosis and management of prostate cancer. While transrectal ultrasound and, subsequently, multiparametric magnetic resonance imaging (mpMRI) have become well-established modalities in the initial diagnosis of prostate cancer, numerous techniques for the distant staging of prostate cancer have all suffered from significant limitations.

Written by Zachary Klaassen, MD, MSc
June 22, 2021
An accurate assessment of the extent of disease is critical to the care of patients with cancer, across the natural history of disease including initial evaluation, following local treatment, and assessing response to systemic therapy. Thus, improvements in radiographic imaging may revolutionize
Written by Zachary Klaassen, MD MSc
April 15, 2021
Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein which functions as a zinc metalloenzyme and is found on prostatic epithelium. In normal prostate tissue, PSMA expression and localization focuses on the cytoplasm and apical side of the epithelium surrounding prostatic ducts.
May 20, 2020
The purpose of this document is to describe the appropriate use of imaging in the diagnostic evaluation of patients with BCR after definitive primary treatment. The imaging modalities that were considered included CT, bone scan, and the U.S. Food and Drug Administration (FDA)–approved PET radiotracers that track malignancy-induced lipogenesis (11C-choline) and amino acid metabolism (18F-fluciclovine). 
Conference Coverage
Conference Highlights Written by Physician-Scientist
Presented by Jiarou Wang, MD
At the 2024 SNMMI annual meeting Dr. Jiarou Wang discussed the diagnostic performance of 68Ga-P16-093 in newly diagnosed prostate cancer. 68Ga-P16-093 is a novel PSMA-targeted radiopharmaceutical that has a labeling reaction compatible with various Ge/Ga generators and has a simple labeling method of heating at 95 degrees Celsius for 5 minutes, leading to high radiochemical purity. As a targeting agent in prostate cancer patients,
Presented by Luke Nordquist, MD
(UroToday.com) The 2024 Society of Nuclear Medicine & Molecular Imaging (SNMMI) annual meeting featured a session on prostate cancer, and a presentation by Dr. Luke Nordquist discussing results of COBRA, an assessment of the safety and efficacy of 64Cu-SAR-bisPSMA in patients with biochemical recurrence of prostate cancer following definitive therapy.
Presented by Jean-Mathieu Beauregard, MD, MSc, FRCPC
The 2024 SNMMI annual meeting featured a session on prostate cancer, and a presentation by Dr. Jean-Mathieu Beauregard discussing a sub-analysis of the 3TMPO study assessing eligibility for PSMA radioligand therapy based on dual FDG/PSMA-PET. Eligibility criteria for PSMA radioligand therapy are currently debated, particularly with respect to the role of FDG-PET in patient selection.
Presented by Linlin Li, PhD
The 2024 SNMMI annual meeting featured a session on prostate cancer, and a presentation by Dr. Linlin Li discussing the dosimetry and pilot therapy study of novel PSMA-targeting agents, 177Lu-P17-087 and 177Lu-P17-088, in metastatic castration-resistant prostate cancer patients. 
Presented by Thomas Hope, MD
The 2024 SNMMI annual meeting was host to the session Novel Approaches and Combination Therapies; Pre-Targeting Approaches. Dr. Thomas Hope discussed the combination treatment of prostate cancer using Pembrolizumab with PSMA-based radioligands.
Presented by Nat Lenzo, MD, EMBA, FRACP, FAANMS, GAICD
At the 2024 SNMMI annual meeting, Dr. Nat Lenzo presented preliminary results of ProstACT SELECT, specifically the safety, tolerability, and dosimetry of TLX591 with best standard of care in patients with PSMA-expressing metastatic castration resistant prostate cancer.
Presented by Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, FICI
The 2024 SNMMI annual meeting featured the Therapy Center of Excellence Saul Hertz Lecture and Award, and a presentation by Dr. Michael Hofman discussing bridging evidence-based medicine and precision oncology. Saul Hertz (1905-1950) conceived and brought from bench to bedside radioactive iodine for medical uses based on the 1936 question “Could iodine be made radioactive artificially?” This was followed by the 1937 radioactive iodine studies assessing thyroid physiology, tracer qualities, dosimetry, and thyroid carcinoma. 
Presented by James Buteau, MD, FRACP, FRCPC
Th SNMMI 2024 Annual Meeting was host to a prostate cancer novel approaches and combination therapies session. Dr. James Buteau discussed novel approaches of combination PSMA-based radiopharmaceutical treatments for prostate cancer.
Presented by David Chen, PhD
At the SNMMI 2024 Annual Meeting, David Chen presented the results of a prospective analysis of the ProsTIC registry evaluating the oncologic and quality-of-life outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients with a stable or poor initial PSA response to [177Lu]Lu-PSMA-617, and the prognostic value of baseline imaging biomarkers and dosimetry.
Presented by Meryam Losee, BS
At the SNMMI 2024 Annual Meeting, Dr. Meryam Losee presented the results of a study evaluating the effect of bone marrow disease on hematologic toxicity and PSA response to 177Lu-PSMA-617 therapy. 
Presented by Benjapa Khiewvan, MD
At the SNMMI 2024 Annual Meeting Dr. Benjapa Khiewvan presented the first Thai experience with Lu-177-PSMA-I&T treatment for patients with metastatic castrate-resistant prostate cancer (mCRPC).
Presented by Fuad Novruzov, MD, PhD
At the SNMMI 2024 Annual Meeting Dr. Fuad Novruzov presented the results of a prospective phase 3 randomized study from Azerbaijan evaluating 225Ac-PSMA + 177Lu-PSMA tandem therapy for metastatic castration-resistant prostate cancer (mCRPC).
Presented by Vishnu Murthy
At the SNMMI 2024 Annual Meeting Vishnu Murthy presented the results of a US expanded access program evaluating the efficacy and toxicity of 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting and compared these results to those from the phase 3 VISION trial.
Presented by Oliver Sartor, MD
At the SNMMI 2024 Annual Meeting Dr. Oliver Sartor presented the updated results of PSMAfore, a phase 3 trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (mCRPC).
Presented by Oliver Sartor, MD
The SNMMI 2024 Annual Meeting was host to a prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) tumor board session. Dr. Oliver Sartor discussed whether earlier use of PSMA RLT in earlier settings is of clinical benefit.
Presented by Josef Zahner, PhD
At the SNMMI 2024 Annual Meeting, Dr. Josef Zahner presented the first dosimetry results of a study evaluating the influence of androgen receptor pathway inhibitors (ARPIs) on absorbed doses in metastatic castrate-resistant prostate cancer (mCRPC) patients undergoing 177Lu-PSMA-617 therapy.
Presented by  Michael Gorin, MD
The 2024 ASCO annual meeting was host to a presentation by Dr. Michael Gorin, who presented CLARIFY, a phase III diagnostic study of positron emission tomography (PET) using 64Cu-SAR-bisPSMA in patients with high-risk prostate cancer prior to radical prostatectomy.
Presented by Luke Nordquist, MD, FACP
The 2024 ASCO annual meeting featured a session on prostate cancer, and a presentation by Dr. Luke Nordquist discussing results of COBRA, an assessment of the safety and efficacy of 64Cu-SAR-bisPSMA in patients with biochemical recurrence of prostate cancer following definitive therapy.
Presented by Rui M. Bernardino, MD
The 2024 European Association of Urology (EAU) annual meeting featured a session on adverse pathology and imaging for risk assessment and local staging, and a presentation by Dr. Rui Bernardino discussing intraductal prostate cancer affinity for lymphatic-predominant metastases through 18F-DCFPyL-PSMA-PET/CT scans in pre-treatment prostate cancer patients.
Presented by Ken Herrmann, MD
The 2024 European Association of Urology (EAU) annual congress held in Paris, France was host to a plenary session addressing imaging-related controversies for the staging of genitourinary cancers. Professor Ken Herrmann discussed the advantages and pitfalls of molecular imaging for prostate cancer characterization.
Presented by Henk G. van der Poel, MD, PhD
 The 2024 European Association of Urology (EAU) annual congress held in Paris, France was host to a plenary session addressing imaging-related controversies for the staging of genitourinary cancers. Professor Henk van der Poel discussed why patients with prostate-specific membrane antigen (PSMA)-detected M1a disease should be treated similarly to patients with conventional imaging-detected M0 disease.
Presented by Louise Emmett, MBChB, FRACP
In the Discussant session at the 2023 ASCO annual meeting, Dr. Louise Emmett discussed the current and future states of novel imaging modalities for advanced prostate cancer, highlighting three abstracts from this session.
Presented by Thomas A. Hope, MD
(UroToday.com) At the 2022 American Society of Clinical Oncology Annual Meeting held in Chicago and virtually, a breakout session assessing the best approaches and treatment updates in biochemically recurrent prostate cancer featured a presentation from Dr. Thomas A. Hope discussing the manner in which molecular-based imaging is defining the landscape of prostate cancer.
Presented by William J. Aronson, MD
In a podium presentation at the Friday morning plenary of the 2022 American Urologic Association Annual Meeting held in New Orleans and virtually, Dr. William Aronson presented a State-of-the-Art Lecture on prostate specific membrane antigen (PSMA) Diagnostics and Theranostics.
Presented by Michael Hofman, MBBS (Hons), FRACP, FAANMS, FICIS
The 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting included a session on the management of metastatic hormone sensitive prostate cancer (mHSPC) and a presentation by Dr. Michael Hofman discussing how frequent low-volume disease on conventional imaging becomes high-volume on next-generation imaging. Dr. Hofman started his presentation by noting that there has been an explosion of PSMA PET publications per year from 2001 to 2021:
Presented by Michael Morris, MD
The 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting included a session on the management of non-metastatic castrate-resistant prostate cancer (nmCRPC), and a presentation by Dr. Michael Morris discussing the advantages of using novel imaging in this disease space.
Presented by Ken Herrmann, MD, MBA
The 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting included a session on high-risk and locally advanced prostate cancer and a presentation by Dr. Ken Herrmann discussing the impact of next generation imaging and the optimal tracer for PET-based imaging for staging.
Presented by Jason Efstathiou, MD
The 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting included a session on high-risk and locally advanced prostate cancer and a presentation by Dr. Jason Efstathiou arguing for changes in management based on next-generation imaging.
Presented by Gerald L. Andriole, Jr, MD
The SUO annual meeting included a prostate cancer session and a presentation by Dr. Gerald Andriole discussing the impact of 18F-fluciclovine PET/CT on plans for ADT in patients with biochemical recurrence of prostate cancer. 
Presented by Robert Reiter, MD
The SIU 2021 annual meeting focused on the role of prostate-specific membrane antigen (PSMA) and theranostics in prostate cancer, Dr. Robert Reiter began with a presentation on the role of PSMA-based imaging as a diagnostic tool in the initial staging of patients with prostate cancer.
Presented by Ephraim E. Parent, MD
In a special session of the ASTRO and SNMMI held at the 2021 ASTRO Annual Congress, Dr. Parent presented on the role of molecular imaging and targeted radionuclide therapy using PSMA-based radiopharmaceuticals.
Presented by Bital Savir-Baruch, MD
In a special session of the American Society for Radiation Oncology (ASTRO) and Society of Nuclear Medicine and Molecular Imaging (SNMMI) held at the 2021 ASTRO Annual Congress, Dr. Baruch presented on the role of molecular imaging using Fluciclovine PET imaging.
Presented by Alberto Bossi, MD
Dr. Alberto Bossi discussed radiotherapy after radical prostatectomy in the PSMA-PET era. Adjuvant radiotherapy is defined as immediate postoperative radiation in the case of extraprostatic extension, positive margins, seminal vesicle infiltration, high Gleason score, or pN+ disease. Salvage radiotherapy is defined as a wait-and-see policy in that radiation is only given in the case of a rising postoperative PSA.
Presented by obias Maurer, MD
The treatment for metastatic hormone-sensitive prostate cancer plenary session at the European Association of Urology 2021 Meeting included a presentation by Dr. Tobias Maurer discussing the role of imaging-guided surgical treatment for recurrent metastatic hormone sensitive prostate cancer (mHSPC).
Presented by Karim Fizazi, MD, Ph.D
Dr. Karim Fizazi finished off the thematic session of Treatment Sequencing in Metastatic Prostate Cancer with a presentation on the role of PSMA in diagnostics and treatment of metastatic prostate cancer.
Presented by Michael S. Hofman, MBBS (Hons), FRACP, FAANMS,
The game changing session of the European Association of Urology (EAU)’s 2021 annual meeting included a presentation by Dr. Michael Hofman from the Peter MacCallum Cancer Centre discussing the phase 2 trial of 177Lu-PSMA-617, TheraP, as well as important contrasts/differences between TheraP and VISION.
Presented by Johann De Bono, MD, MSc, Ph.D., FRCP, FMedSci
The EAU 2021 Annual Meeting included a presentation by Johann De Bono discussing the VISION trial, a phase 3 study of 177Lu-PSMA-617 in patients with mCRPC. As PSMA is highly expressed in prostate cancer and mCRPC lesions, the combination of PSMA-617 with the beta-emitter lutetium allows for the targeted delivery of ß-particle radiation to PSMA-expressing cells and the surrounding microenvironment.
Presented by Mary-Ellen Taplin, MD
Following Micheal Morris’s presentation of the results of the phase III VISION trial of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer in the Plenary Session of the 2021 ASCO, Dr. Mary-Ellen Taplin from the Dana Farber Cancer Institute provided a discussant overview of these data and helped to contextualize how we may apply them to our practices.
Presented by Micheal Morris, MD
In a plenary presentation at the 2021 ASCO Annual Meeting, Dr. Morris presented the first results of the VISION trial, a phase III study assessing lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
Presented by Mike Machaba Sathekge, MD, Ph.D
In a plenary presentation in the Progress and Promise in Treatment Personalization for Advanced Prostate Cancer session at the 2021 American Society of Clinical Oncology Genitourinary (Cancers Symposium (ASCO GU), Dr. Sathekge provided a talk examining the role of Lutetium in prostate cancer.
Presented by James Wysock, MD, MSc
At the Society of Urologic Oncology (SUO) Annual Meeting, Dr. James Wysock gave an update on the imaging for primary prostate cancer. Dr. Wysock briefly touched on imaging strategies in both the screening and diagnosis of localized prostate cancer.
Presented by Matthew R. Cooperberg, MD, MPH and Tanya B. Dorff, MD
To conclude the advances in prostate cancer session Drs. Matthew Cooperberg and Tanya Dorff debated whether prostate-specific membrane antigen (PSMA) imaging should be routinely used in the clinical management of prostate cancer.
Presented by Declan Murphy, MB, BCH, BaO, FRACS, FRCS, Urol
At the 2020 virtual Society of Urologic Oncology's (SUO) prostate cancer session, Dr. Declan Murphy discussed the role of prostate-specific membrane antigen (PSMA) scanning in prostate cancer staging. Dr. Declan Murphy states that PSMA PET/CT is an obvious challenger to conventional imaging.
Presented by Declan Murphy, MB, BCH, BaO, FRACS, FRCS, Urol
(UroToday.com) During the Individualized Approach in Advanced Prostate Cancer session at the European Multidisciplinary Congress on Urological Cancers (EMUC) 2020 virtual meeting, Dr. Declan Murphy presents on using prostate-specific membrane antigen (PSMA) positron emission tomography (PET) for upfront staging in high-risk prostate cancer disease. Dr. Murphy states that PSMA PET/CT is an obvious challenger to conventional imaging.
Presented by Renu Eapen, MD
The Société Internationale d'Urologie (SIU) 2020 Virtual Annual Congress featured a debate discussing imaging definitions for oligometastatic prostate cancer. Dr. Renu Eapen from Australia argued that oligometastatic disease should be defined based on novel imaging modalities.
Presented by Noel William Clarke, MD
The Société Internationale d'Urologie (SIU) 2020 Virtual Annual Congress featured a debate discussing imaging definitions for oligometastatic prostate cancer. Dr. Noel Clarke from the United Kingdom argued that oligometastatic disease should be defined based on standard imaging modalities.
Presented by Michael S. Hofman, MBBS (Hons), FRACP, FAANMS,
(UroToday.com) As part of the “Game-Changing Session 1” plenary presentation at the 2020 European Association of Urology (EAU) Virtual Annual Meeting, Dr. Michael Hofman presented results of the proPSMA study which was recently published in the Lancet.1
Presented by Scott T. Tagawa, MD, MS, FACP
There are currently significant imaging deficiencies for men with prostate cancer (Figure 1), with the hope that PSMA imaging-based modalities will address a significant gap in this field. Prostate-specific membrane antigen PSMA is a transmembrane glycoprotein with folate hydrolase activity.
Presented by Michael J. Morris, MD
Men with biochemically recurrent prostate cancer after definitive local therapy currently have limited imaging modalities in the United States which are sensitive or specific enough to detect tumor recurrence. PSMA PET scans can improve on this detection by detecting cells expressing PSMA protein on their cell surface.
Presented by Charles J. Ryan, MD, & Markus Graefen, MD
San Francisco, California (UroToday.com)  The first case presented was that of a 54-year-old otherwise healthy man who underwent radical prostatectomy after biopsy-confirmed prostate cancer.
Presented by Jeremie Calais, MD
San Francisco, California (UroToday.com) Advanced imaging is increasingly being used across all stages of prostate cancer. Dr. Jeremie Calais from UCLA Medical Center discussed
Presented by Claire M. De La Calle, MD
Washington, DC (UroToday.com) While PSA screening has resulted in decreasing prostate cancer mortality, PSA is also known to be a poorly specific test for the detection of clinically
Presented by Renu Eapen, FRACS
Athens, Greece (UroToday.com) Dr. Renu Eapen gave an overview of the role of PET- prostate-specific membrane antigen (PSMA) in prostate cancer and gave a preview of what is to come
Presented by Sigrid Carlsson, MD, PhD, MPH
Athens, Greece (UroToday.com) Dr. Carlsson gave an encompassing presentation on prostate cancer screening from the perspective of an epidemiologist.
Presented by Cora Sternberg, MD
Barcelona, Spain (UroToday.com)  Dr. Cora Sternberg summarized the findings from several posters, including three immunotherapy phase 1 or 2 trials, a phase 2 trial of 177Lu-PSMA-617,
Presented by Scott T. Tagawa, MD, MS
Barcelona, Spain (UroToday.com) PSMA is overexpressed in prostate cancer with limited expression in other organs. Furthermore, prostate cancer is radiosensitive with dose-response (
Presented by Stefano Fanti, MD
Barcelona, Spain (UroToday.com) Theranostics is an emerging field of medicine which utilizes targeted cancer therapy based on specific molecular-targeted diagnostic tests. As part of the Imaging in Prostate Cancer plenary session at the 2019 European Association of Urology (EAU) annual meeting in Barcelona, Spain
Presented by Olivier Rouvière, MD, PhD
Barcelona, Spain (UroToday.com) Dr. Rouviere presented the imaging specialist’s perspective on MRI use in prostate cancer. According to the European Association of Urology (EAU) guidelines prostate multiparametric MRI (mpMRI) was originally recommended after a negative prostate biopsy
Presented by Michael Hofman, FRACP, MBBS

San Francisco, CA (UroToday.com) PSMA is over-expressed in all prostate tissue, including prostatic carcinoma. Lutetium-177 (177Lu)-PSMA617 (LuPSMA) is a small radiolabeled molecule which binds to PSMA

Presented by Jeremie Calais, MD, MSc
San Francisco, CA (UroToday.com)  Salvage radiotherapy (SRT) for prostate cancer biochemical recurrence after radical prostatectomy (RP) is commonly administered to patients with PSA < 1 ng/mL, a threshold at which standard-of-care imaging 
Presented by Paul L. Nguyen, MD
Prague, Czech Republic (UroToday.com) Dr. Paul Nguyen took the stance for radiation therapy in this much-anticipated debate regarding appropriate local treatment in men with high risk localized prostate cancer. Dr. Nguyen notes that high-quality radiation therapy for high-risk disease needs long-term ADT and a brachytherapy boost.